RVMD has surged 492% over one year on daraxonrasib’s landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival. <\/p>\n<\/li>\n
MRK ranks as the most likely acquirer, with Keytruda’s patent cliff mounting pressure and CEO Robert Davis pledging to diversify its growth portfolio. <\/p>\n<\/li>\n
It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself<\/a> (Sponsor) <\/p>\n<\/li>\n<\/ul>\n Revolution Medicines<\/strong> (NASDAQ:RVMD<\/a>) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform a market cap of $44.1 billion. The stock is up 158.1% year to date, 492.4% over one year, and 664.1% over five years. Liquidity stands at $3.94 billion in cash and marketable securities, bolstered by $2.23 billion in spring 2026 capital raises and up to an additional $1.5 billion available under Royalty Pharma arrangements. FY2026 GAAP operating expenses are guided to $2.10 billion to $2.20 billion. There is no product revenue yet, EPS runs at \u2212$8.87 for the trailing 12 months, and no deal talks have been confirmed. <\/p>\n RAS mutations drive roughly 30% of cancers, and Revolution has the deepest late-stage RAS(ON) pipeline in biotech. Lead asset daraxonrasib delivered median overall survival of 13.2 months versus 6.7 months for chemo in second-line pancreatic cancer (HR 0.40; p<0.0001). The FDA accepted the NDA and granted Priority Voucher review. CEO Mark Goldsmith called it “a transformational period” tied to “unprecedented Phase 3 results.” Elironrasib (85% ORR in 1L G12C NSCLC), zoldonrasib (82% ORR in G12D NSCLC), and RMC-5127 underscore the scarcity case. <\/p>\n Ranking the Plausible Acquirers <\/p>\n 5. Pfizer<\/strong> (NYSE:PFE<\/a>). CEO Albert Bourla says, “I’m particularly encouraged by what we’re seeing in oncology.” With EBITDA of $25.38 billion and a stretched balance sheet post-Seagen, a more than $50 billion check is a reach. <\/p>\n SoFi Active Invest is offering a limited-time promotion. Open an account, fund it with $50 or more, and you could receive up to $3,000 in complimentary stock<\/a> for Active Invest accounts. See for yourself by clicking here now.<\/a> (Sponsor) <\/p>\n 4. Johnson & Johnson<\/strong> (NYSE:JNJ<\/a>). It has a $626.1 billion market cap, AAA credit, and a stated $50 billion oncology target by 2030. The company already bought Firefly Bio for KRAS degraders. Discipline on price is the offset. <\/p>\n 3. Bristol Myers Squibb<\/strong> (NYSE:BMY<\/a>). Owns Krazati (KRAS G12C) and has an existing clinical collaboration on daraxonrasib plus navlimetostat. The strategic fit is tightest. Net debt near $33.6 billion is the constraint. <\/p>\n 2. Roche.<\/strong> The Genentech oncology machine and Swiss balance sheet make Roche a live bidder for scarce RAS platforms, despite trading outside the United States. <\/p>\n 1. Merck<\/strong> (NYSE:MRK<\/a>). Keytruda posted $8.03 billion in Q1 but faces a patent cliff. CEO Robert Davis pledged to “transform our portfolio to one with a diversified set of growth drivers.” Merck deployed $9.0 billion on Cidara and also pursued Verona, Terns, and Halda. Motive plus means makes Merck the most obvious buyer. <\/p>\n What About Private Equity or Alternative Capital? <\/p>\n A traditional take-private leveraged buyout (LBO) is impractical for a $44 billion pre-revenue company. The realistic alternatives: additional structured royalty tranches (extending the Royalty Pharma facility), a large PIPE anchored by crossover funds, or expanded regional partnerships in the style of the recent BeOne Medicines collaboration. This path ranks below a strategic pharma bid. <\/p>\n What to Watch Analysts are positive and have a mean price target of $214.71. Catalysts include the FDA decision on daraxonrasib, RASolve 307 and colorectal readouts, and any 13D\/13G activity. Insiders were net sellers of roughly $48.6 million over 90 days. <\/p>\n Want Up To $3,000 In Stock? SoFi Is Giving New Active Invest Users Complimentary Stock <\/p>\n Looking to grow your money but unsure where to begin? SoFi Active Invest is offering a limited-time promotion\u2014open a new Active Invest account, fund it with $50 or more, and you could receive up to $3,000 in complimentary stock<\/a>. <\/p>\n From $0 commission trading3 to fractional shares4 and automated investing, this app is designed to simplify investing for everyone, whether you’re just starting or already experienced. Its easy to sign up and secure your bonus.<\/a>(Sponsor) <\/p>\n<\/a> 24\/7 Wall St. Why a Strategic Buyer Would Want It <\/p>\n
<\/a> RVMD Analyst Ratings \u2014 24\/7 Wall St. <\/p>\n